THE UK will become the first country in the world to have a national programme that uses the same vaccine to protect both newborns and older adults against Respiratory Syncytial Virus (RSV).

The rollout, which will start from September 1 in England, includes both a vaccine for pregnant women over 28 weeks to help protect their newborn babies, a routine programme for those over 75, and a one-off campaign for people aged 75 to 79.

These are the groups at the greatest risk from RSV, based on advice from the Joint Committee on Vaccination and Immunisation.

Despite infecting around 90 per cent of children within the first two years of life, RSV is relatively unknown among the public.

It typically causes mild, cold-like symptoms. However, it can lead to severe lung infections like pneumonia and infant bronchiolitis and is a leading cause of infant mortality globally.

Each year in the UK, RSV accounts for around 30,000 hospitalisations in children aged under five and is responsible for 20 to 30 infant deaths. Up to 50 per cent of hospital admissions for children under one year old relate to RSV.

It also causes around 9,000 hospital admissions in those aged over 75.  The RSV programme could free up thousands of hospital bed days and help to avoid hundreds of deaths each year.

More than 75,000 people in Devon will be eligible for the vaccine when it becomes available.

Dr Alex Degan, a GP and Primary care medical director for NHS Devon, said: “This new vaccine offers huge opportunities to prevent severe illness in those most vulnerable to RSV, helping to protect lives and ease winter pressures for the NHS.

“We are working local healthcare teams, including GPs and midwives, and Local Authority colleagues to be ready to provide vaccinations from September.

“You will be contacted about local arrangements, please do come forward if you are eligible. Look out for information from your GP regarding where and when you can get your RSV vaccination.  The vaccination will be available throughout the year, but we strongly encourage people to come forward in September to ensure they have protection in time for winter when spread of the virus is at its peak.”

Minister for Public Health and Prevention, Andrew Gwynne, said: “As someone who has seen the devastating effects of RSV firsthand, I am thrilled to see the UK leading in the way in tackling this devastating disease.

“My own grandson contracted RSV when he was just days old, leading to weeks in intensive care, and a lifelong impact on his health. I don’t want anyone to go through what he went through.

“Not only will this vaccine save lives and protect the most vulnerable, it will help ease pressure on our broken NHS, freeing up thousands of hospital beds as we head into winter.”

People aged 75-79 years old on September 1, 2024 will be invited to receive their RSV vaccination with their GP, and those turning 75 after this date will also receive an invitation from their GP once eligible. 

Women that are at least 28 weeks pregnant will be contacted by their maternity service or GP surgery to get the vaccine to protect their baby from September.

These vaccination programmes will save lives and significantly reduce the burden on the NHS during the challenging winter months.

The vaccine has been developed and produced by Pfizer. The programme follows the advice from the independent Joint Committee on Vaccination and Immunisation (JCVI) published in September 2023.